These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 31612411)

  • 21. New approaches to the pharmacological management of major depressive disorder.
    Witkin JM; Li X
    Adv Pharmacol; 2009; 57():347-79. PubMed ID: 20230766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The contribution of proteomic studies in humans, animal models, and after antidepressant treatments to investigate the molecular neurobiology of major depression.
    Carboni L
    Proteomics Clin Appl; 2015 Oct; 9(9-10):889-98. PubMed ID: 25488430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular mechanism of polysaccharides in combating major depressive disorder: A comprehensive review.
    Kong H; Xu T; Wang S; Zhang Z; Li M; Qu S; Li Q; Gao P; Cong Z
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129067. PubMed ID: 38163510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis?
    Bambico FR; Belzung C
    Curr Top Behav Neurosci; 2013; 15():243-91. PubMed ID: 23271325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders.
    Jiang Y; Zou D; Li Y; Gu S; Dong J; Ma X; Xu S; Wang F; Huang JH
    Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New hypothesis and treatment targets of depression: an integrated view of key findings.
    Cai S; Huang S; Hao W
    Neurosci Bull; 2015 Feb; 31(1):61-74. PubMed ID: 25575479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of oxidative stress in depressive disorders.
    Michel TM; Pülschen D; Thome J
    Curr Pharm Des; 2012; 18(36):5890-9. PubMed ID: 22681168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New agents and perspectives in the pharmacological treatment of major depressive disorder.
    Sanches M; Quevedo J; Soares JC
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110157. PubMed ID: 33159975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder.
    Zheng X; Zhang X; Wang G; Hao H
    Drug Discov Today; 2015 May; 20(5):562-8. PubMed ID: 25849660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking utilising the OliveNet™ library reveals novel phenolic compounds which may potentially target key proteins associated with major depressive disorder.
    Pitsillou E; Liang J; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 Jun; 86():107234. PubMed ID: 32220809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre- and Post-Synaptic protein in the major depressive Disorder: From neurobiology to therapeutic targets.
    Silva RH; Pedro LC; Manosso LM; Gonçalves CL; Réus GZ
    Neuroscience; 2024 Sep; 556():14-24. PubMed ID: 39103041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural basis of major depressive disorder: Beyond monoamine hypothesis.
    Boku S; Nakagawa S; Toda H; Hishimoto A
    Psychiatry Clin Neurosci; 2018 Jan; 72(1):3-12. PubMed ID: 28926161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating the monoamine and cytokine hypotheses of depression: Is histamine the missing link?
    Hersey M; Hashemi P; Reagan LP
    Eur J Neurosci; 2022 May; 55(9-10):2895-2911. PubMed ID: 34265868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neurodegenerative hypothesis of depression and the influence of antidepressant medications.
    Hall S; Parr BA; Hussey S; Anoopkumar-Dukie S; Arora D; Grant GD
    Eur J Pharmacol; 2024 Nov; 983():176967. PubMed ID: 39222740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frontal alpha asymmetry as a pathway to behavioural withdrawal in depression: Research findings and issues.
    Jesulola E; Sharpley CF; Bitsika V; Agnew LL; Wilson P
    Behav Brain Res; 2015 Oct; 292():56-67. PubMed ID: 26051816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dentate gyrus neurogenesis and depression.
    Sahay A; Drew MR; Hen R
    Prog Brain Res; 2007; 163():697-722. PubMed ID: 17765746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.